Recent progress in gene therapy for familial hypercholesterolemia treatment

Area of Science:

• Genetics and Cardiovascular Medicine
• Pharmacology and Therapeutics

Background:

• Familial hypercholesterolemia (FH) is a prevalent genetic disorder affecting 1 in 300 individuals.
• FH leads to elevated cholesterol levels and substantially increased cardiovascular disease risk.
• Current FH treatments have limitations, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review approved gene therapy drugs for hypercholesterolemia.
• To explore gene addition, inactivation, and editing therapies for FH, including those in development.
• To discuss advancements in gene editing tools and safety considerations for gene therapy in FH.

Main Methods:

• Literature review of approved gene therapy drugs.
• Survey of gene addition, inactivation, and editing therapies for hypercholesterolemia.
• Analysis of recent advancements in gene editing technologies and safety profiles.

Main Results:

• Gene therapy presents a promising alternative for FH treatment.
• Various gene therapy approaches (addition, inactivation, editing) are in development.
• Advancements in gene editing tools are crucial for therapeutic applications.

Conclusions:

• Gene therapy holds significant potential to revolutionize FH management.
• Further research and development are essential to overcome safety concerns and optimize efficacy.
• Innovative gene-based treatments could offer a more effective solution for this challenging genetic condition.